FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.7200
+0.0600 (+2.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.6600
Open2.6700
Bid0.0000 x 800
Ask3.2000 x 1300
Day's Range2.6100 - 2.7500
52 Week Range2.4000 - 7.6000
Volume172,377
Avg. Volume398,266
Market Cap148.038M
Beta (3Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of FOMX earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Foamix Pharmaceuticals Ltd Earnings Call

  • Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now
    SmarterAnalyst5 days ago

    Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now

    Get ready, bargain shoppers. Foamix (FOMX) has plummeted 27% since the beginning of the year and it looks like the stock received more lashes than it deserved -- at least, according to Wall Street analysts.2019 is poised to be a transformative year for Foamix. The company's acne treatment FMX101 is currently pending regulatory review in the U.S, and a PDUFA date of October 20, 2019 has been set. Furthermore, Foamix plans to submit a New Drug Application (NDA) for FMX103 during mid-2019, following positive long-term safety data in papulopustular rosacea patients. Now, let's take a closer look at what analysts are expecting ahead of October's FDA decision.FMX101's Approval Chances and ForecastsCredit Suisse analyst Vamil Divan sees a high likelihood of regulatory approval for FMX101, applying a 90% probability of success (POS). The analyst rates FOMX stock an Outperform with a $9.00 price target, which implies nearly 250% upside from current levels. With an FDA approval in hand (100% POS), Divan says his price target will be boosted to $11.00. According to the analyst, "an increase in the sample size (1,507 patients in this trial vs. ~500 each in the two prior trials) and improved site selection and training helped drive statistically significant [clinical] results," which put the company on track to win FDA approval.Similarly, H.C Wainright analyst Ram Selvaraju estimates the probability of regulatory approval at 85%, and assigns a $12.00 price target for the stock. If the price target is reached within 12 months, that would provide a 12-month return of nearly 360%. Selvaraju opined, "We believe that the current valuation situation presents an attractive entry point for value-focused investors, given the fact that Foamix currently trades about 2x book value [...] Our risk-adjusted net present value (rNPV) of FMX101 is $400M, which factors in an 85% probability of regulatory approval [...] We have employed a sum-of-the-parts valuation approach that yields a total projected firm value of $696M, which translates into a price objective of $12.00 assuming ~59M fully-diluted shares outstanding as of end-2019."Commercial Opportunity Selvaraju believes investors seem to be discounting both FMX101 and FMX103 from a commercial standpoint, but "this is unwarranted." Why? "These agents are based on well-known, validated and effective compounds in their respective target indications and have generated statistically significant efficacy data in large, robustlypowered pivotal studies. We also draw investors' attention to the large size and underserved nature of the target markets—namely, acne and rosacea—and the willingness of patients and physicians alike to try new formulations when they are introduced. Furthermore, we point to the user-friendly and well-tolerated nature of the Foamix formulations, which utilize the company's proprietary foam-based delivery technology to enhance efficacy while minimizing off-target systemic side effects," Selvaraju answers.Cowen analyst Ken Cacciatore has recently spoken with 3 dermatology KOLs; they all agreed that "the clinical data were as good or better than they would have expected," and, according to the analyst, one has indicated that "it looked "more impressive" than Aczone (which peaked at over $200MM+ before genericization)." Cacciatore believes that given the wide use of oral minocycline, clinicians are eager to have this option with potential similar efficacy yet without the the systemic side effects, and therefore, the marketing of FMX-101 should be a very easy story to tell. The analyst says "FMX-101 should be able to easily surpass the peak prescription levels of Aczone (via our consultants' feedback)," and "this would place FMX-101 to achieve at least $250MM in revenue." Furthermore, the analyst believes FMX-101 could ultimately reach his target of $350MM given what he believes will be "improved efficacy/outcomes." Cacciatore argues that "even undifferentiated dermatology assets are selling at 3x peak revenue. Using just FMX-101 alone – and the low-end ($250MM) of what we believe will be the ultimate product size – would yield a value of $750MM, or $13-15 per share."Bottom lineFoamix has seen its shares struggle mightily this year, but analysts continue to believe that this beaten-down biotech stock is a sure-fire winner. Analysts are confident that lead asset, FMX101, has substantial potential in treating acne, with an upcoming October 20, 2019 PDUFA date as a key potential positive catalyst for FOMX shares.This latest pullback has arguably skewed the risk-to-reward ratio for the better -- perhaps making FOMX an attractive buy for risk-tolerant investors. More recent articles from Smarter Analyst: * Aurora Cannabis Lost Money in Q3 -- And That's Okay? * Gene Munster: Key Takeaways From Nvidia (NVDA) Earnings * Trade War? Top Analyst Says Alibaba (BABA) Stock Still a Buy * The Green Organic Dutchman (TGODF) Stock -- Not Sinking Exactly, But Not Sailing Anywhere Fast

  • Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds
    Simply Wall St.11 days ago

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript
    Motley Fool11 days ago

    Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript

    FOMX earnings call for the period ending March 31, 2019.

  • Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks13 days ago

    Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -16.67% and -67.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    Foamix: 1Q Earnings Snapshot

    The Rehovot, Israel-based company said it had a loss of 28 cents per share. The acne treatment developer posted revenue of $308,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
    Zacks20 days ago

    Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know

    Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • This Small-Cap Biotech Stock Could Triple in 2019
    GuruFocus.comlast month

    This Small-Cap Biotech Stock Could Triple in 2019

    Investing in biotech stocks can provide true binary opportunities. If the drug succeeds, small-cap biotech stocks easily become multi-baggers. Warning! GuruFocus has detected 2 Warning Signs with FOMX.

  • What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?
    Simply Wall St.2 months ago

    What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Anyone researching Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) might want to consider the historical volatility of the share pr...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FOMX earnings conference call or presentation 1-Mar-19 1:30pm GMT

    Q4 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?
    Simply Wall St.3 months ago

    How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • Are Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Interest Costs Too High?
    Simply Wall St.4 months ago

    Are Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Interest Costs Too High?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy?
    Insider Monkey5 months ago

    Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • Simply Wall St.5 months ago

    Could Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Investor Composition Influence The Stock Price?

    A look at the shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • Benzinga6 months ago

    The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of FOMX earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks6 months ago

    Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -22.58% and -21.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Reuters6 months ago

    Foamix's treatment for common skin condition meets late-stage trial goals

    Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials. The treatment, code-named FMX103 and made up of an antibiotic commonly used to treat infections, significantly reduced inflammatory lesions, compared to a foam without the antibiotic, minocycline. The two late-stage studies enrolled over a thousand patients suffering from papulopustular rosacea, which causes lesions to break out on the face, and the mostly commonly reported side effects were upper respiratory tract infections, the company said.

  • Implied Volatility Surging for Foamix (FOMX) Stock Options
    Zacks7 months ago

    Implied Volatility Surging for Foamix (FOMX) Stock Options

    Investors need to pay close attention to Foamix (FOMX) stock based on the movements in the options market lately.

  • Simply Wall St.7 months ago

    Does Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Have A High Beta?

    If you own shares in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Foamix's Acne Candidate Succeeds in Study, Shares Rally
    Zacks8 months ago

    Foamix's Acne Candidate Succeeds in Study, Shares Rally

    Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.